Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 15CNS 6Gastrointestinal 5Gynecologic 4Tumor-Agnostic 2Thoracic 2Sarcoma 2Other solid neoplasm 2Head & Neck 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Treatment for Metastatic or Locally Advanced Cervical Cancer 1Pancreatic Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Endometrial Cancer 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × NVP-BKM120 × Gynecologic × Clear all
NCT01068483 2020-12-08

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Novartis

Phase 1 Completed
107 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Array BioPharma

Phase 1 Completed
89 enrolled
BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Novartis

Phase 2 Completed
70 enrolled 8 charts
Gynecologic

Advanced Endometrial Cancer

NCT01613677 2017-04-20

Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer

Novartis

Phase 2 Withdrawn
Gynecologic

Treatment for Metastatic or Locally Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡